Australia's most trusted
source of pharma news
Friday, 13 February 2026
Posted 13 February 2026 AM
AstraZeneca has doubled down on its target to deliver US$80 billion in total revenue by 2030, with plans to build a portfolio of more than 25 blockbusters by the end of the decade.
The British pharmaceutical giant capped 2025 with fourth-quarter revenues of US$15.5 billion, thanks to the company’s oncology portfolio which contributed US$7 billion to that figure.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.